title: [Effects of aprepitant in daily administrations of low-dose cisplatin].
abstract: OBJECTIVE
  While aprepitant is actually recommended for the prevention of nausea and vomiting induced by a single cisplatin administration, it is still unclear whether it has a clinical benefit when administered along with daily administrations of low- dose cisplatin(20mg/m2 days 1-5). This study was conducted to evaluate the efficacy of aprepitant in patients receiving daily administration of low-dose cisplatin.
  
  
  METHODS
  Our study focused on 25 patients who received cancer therapy including cisplatin, with or without aprepitant (days 1-5). We performed a retrospective study to identify any significant positive effect of aprepitant in the prevention of nausea and vomiting for 10 days(days 1-10). Because cisplatin has a long half-life, we assessed the delayed phase nausea and vomiting(days 6-10).
  
  
  CONCLUSIONS
  Multiple-day dosing of aprepitant was effective for prevention of nausea(Odds ratio: 0. 30, p= 0. 0012)and vomiting(Odds ratio: 0. 04, p=0. 0001)throughout the observation. Furthermore, we observed a significant positive effect of aprepitant in the prevention of delayed nausea(Odds ratio: 0. 19, p=0. 0083)and vomiting(Odds ratio: 0. 07, p=0. 0040). These findings suggest that multiple-day dosing of aprepitant is useful for the inhibition of acute delayed nausea and vomiting caused by chemotherapy including daily administration of low-dose cisplatin.
authors.affiliation: Dept. of Pharmacy, Kobe University Hospital, Japan.
authors.forename: Misato
authors.initials: M
authors.lastname: Kariya
authors.forename: Kenta
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kumiko
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Manabu
authors.initials: M
authors.lastname: Kume
authors.forename: Hiroo
authors.initials: H
authors.lastname: Makimoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hirano
authors.forename: Hideaki
authors.initials: H
authors.lastname: Miyake
authors.forename: Masato
authors.initials: M
authors.lastname: Fujisawa
authors.forename: Midori
authors.initials: M
authors.lastname: Hirai
mesh_terms: D000328:Adult; D000077608:Aprepitant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D012189:Retrospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D009025:Morpholines; D000077608:Aprepitant; D002945:Cisplatin